Safety of continuous and intermittent endocrine therapy for advanced prostate cancer and its influences on miR-34b and miR-320a
Objective To explore the safety of continuous and intermittent endocrine therapy for advanced prostate cancer and its influences on miR-34b and miR-320a.Methods A total of 150 patients with advanced prostate cancer admitted in our hospital from March 2018 to May 2021 were selected as the research objects.According to different treatment schemes,the patients were divided into control group and observation group,with 75 cases in each group.The control group received continuous endocrine therapy,and the observation group received intermittent endocrine therapy.The therapeutic effects of the two groups were compared.Results The total incidence of adverse reactions in the observation group was lower than that in the control group(P<0.05).After 28 d of treatment,the miR-34b and miR-320a in the observation group were higher than those in the control group,and the level of prostate specific antigen(PSA)was lower than that in the control group(P<0.05).After 28 d of treatment,the maximum urinary flow rate(Qmax)of the observation group was higher than that of the control group,and the prostate volume(PV)and post void residual(PVR)were lower than those of the control group(P<0.05).After 28 d of treatment,the scores of gastrointestinal symptoms,urinary tract symptoms and treatment-related symptoms in the observation group were lower than those in the control group,and the score of sexual function was higher than that in the control group(P<0.05).Conclusion Intermittent endocrine therapy is effective in the treatment of advanced prostate cancer,it can regulate the expression of miR-34b,miR-320a and PSA,improve urinary function,promote the improvement of quality of life,and has higher safety,which is worth promoting.
continuous endocrine therapyintermittent endocrine therapyadvanced prostate cancerquality of life
NETL
NSTL
万方数据
维普
